Kyoto, Japan

Katsuo Matsuzaka

This inventor holds 8 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: Sekisui Chemical Co., Ltd., Sekisui Seikei, Ltd.. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katsuo Matsuzaka. Retrieved from https://idiyas.com/inventor/katsuo-matsuzaka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 25.0


Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 84(Granted Patents)


Company Filing History:


Years Active: 2003-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Journey of Katsuo Matsuzaka

Introduction: Katsuo Matsuzaka, a distinguished inventor hailing from Kyoto, JP, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Matsuzaka's latest patents include advancements in artificial intelligence algorithms for autonomous vehicles and cutting-edge medical devices for minimally invasive surgeries.

Career Highlights: With a career spanning over two decades, Matsuzaka has been at the forefront of technological advancements, holding numerous patents in various fields such as robotics, biotechnology, and renewable energy.

Collaborations: Throughout his career, Matsuzaka has collaborated with leading research institutions, universities, and multinational companies to bring his inventions to life and make a lasting impact on society.

Conclusion: Katsuo Matsuzaka's relentless pursuit of innovation and his passion for pushing the boundaries of technology have solidified his position as a visionary inventor in the global landscape of inventions and patents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…